Page last updated: 2024-09-04

ezetimibe and Liver Steatosis

ezetimibe has been researched along with Liver Steatosis in 42 studies

Research

Studies (42)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	11 (26.19)	29.6817
2010's	28 (66.67)	24.3611
2020's	3 (7.14)	2.80

Authors

Authors	Studies
Canet, MJ; Cherrington, NJ; Fisher, CD; Hardwick, RN; Street, SM	1
Farrell, GC; Horn, CL; Ioannou, GN; Morales, AL; Savard, C	1
Suzuki, H; Takada, T; Toyoda, Y; Yamanashi, Y	1
Ahn, SH; Han, KH; Kim, BK; Kim, DY; Kim, SU; Lee, WD; Park, JY	1
Arrese, M; Bizama, C; Espinoza, JA; Ferreccio, C; García, P; Gómez, N; González, X; Guevara, F; Kalergis, AM; Lobos-González, L; Miquel, JF; Muñoz-Durango, N; Roa, JC; Rosa, L; Saavedra, N; Villegas, J; Wichmann, IA	1
Bae, SH; Cha, BS; Han, DH; Kang, ES; Kim, B; Kim, G; Kim, I; Kim, KH; Kim, SH; Lee, BW; Lee, M; Lee, MS; Lee, YH; Song, YM; Wang, HJ; Yoo, JE	1
Farrell, GC; Gan, LT; Haigh, WG; Ioannou, G; Larter, CZ; Teoh, NC; Van Rooyen, DM; Yeh, MM	1
Kashiwagi, A; Kume, S; Maegawa, H; Maeno, Y; Morino, K; Nagai, Y; Nishio, Y; Sekine, O; Ugi, S; Ushio, M; Yoshizaki, T	1
Arita, E; Honda, A; Horai, Y; Irie, J; Itoh, H; Kaneko-Iwasaki, N; Miyazaki, T; Morimoto, K; Sugizaki, T; Watanabe, M	1
Chang, E; Kim, L; Lee, WY; Oh, KW; Park, CY; Park, SE; Park, SW; Rhee, EJ	1
Adibkia, K; Asadpour-Zeynali, K; Barzegar-Jalali, M; Garjani, A; Hamishehkar, H; Jahangiri, A; Javadzadeh, Y	1
Kanno, K; Kishikawa, N; Mizooka, M; Sugiyama, A; Tazuma, S; Yokobayashi, K	1
Abel, T; Dinya, E; Fehér, J; Gamal Eldin, M; Kovács, A	1
Fujita, K; Inamori, M; Kirikoshi, H; Kubota, K; Masaki, N; Mizoue, T; Nagashima, Y; Nakajima, A; Nozaki, Y; Saito, S; Shinohara, Y; Takahashi, H; Terauchi, Y; Wada, K; Yoneda, M	1
Ishii, H; Kawakami, A; Nomura, M; Yoshida, M	1
Abel, T; Dinya, E; Eldin, MG; Fehér, J; Kovács, A	1
Enjoji, M; Nakamuta, M	1
Barrett, PH; Chan, DC; Gan, SK; Ooi, EM; Watts, GF	1
Enjoji, M; Kato, M; Kohjima, M; Kotoh, K; Machida, K; Matsunaga, K; Nakamuta, M; Nakashima, M	1
Ahmed, MH	1
Machann, J; Pfeiffer, AF; Rudovich, NN; Weickert, MO	1
Fujii, H; Kawada, N; Ogawa, T; Yoshizato, K	1
Ahmed, MH; Byrne, CD	2
Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Nakamura, T; Nako, H; Ogawa, H; Tokutomi, Y; Yasuda, O	1
Fukui, M; Hasegawa, G; Itoh, Y; Kitawaki, J; Minami, M; Mitsuyoshi, H; Nakamura, N; Obayashi, H; Ohta, M; Okanoue, T; Park, H; Shima, T; Yamaguchi, K; Yasui, K; Yoshikawa, T	1
Fukui, M; Hasegawa, G; Itoh, Y; Minami, M; Mitsuyoshi, H; Nakamura, N; Obayashi, H; Ohta, M; Okanoue, T; Park, H; Shima, T; Yamaguchi, K; Yasui, K; Yoshikawa, T	1
Aburatani, H; Aoki, K; Iwasaki, T; Kadowaki, T; Kubota, N; Mori, S; Muraoka, T; Nakamura, A; Shinoda, K; Terauchi, Y; Tokuyama, K	1
Betters, JL; Jia, L; Yu, L	1
Yoshida, M	1
Fujita, K; Imajo, K; Kirikoshi, H; Mawatari, H; Nakajima, A; Saito, S; Yoneda, M	1
Jiang, ZY; Parini, P; Pramfalk, C	1
Gotoh, T; Hashimoto, M; Kawanami, Y; Moritani, A; Shiwa, T; Yokoyama, T	1
Cassader, M; Gambino, R; Musso, G	1
Fujisawa, K; Kuwashiro, S; Matsumoto, T; Nishina, H; Oishi, T; Sakaida, I; Terai, S	1
Matsui, T; Nakamura, K; Sato, T; Takeuchi, M; Yamagishi, S	1
Ahmed, MH; Osman, MM; Saad, RA	1
Hughes, EA; Patel, J; Singhal, S; Tracey, I	1
Assy, N; Bersudsky, I; Grozovski, M; Hussein, O; Szvalb, S	1
Deushi, M; Haraguchi, M; Ishii, H; Ito, M; Kawakami, A; Nomura, M; Okazaki, M; Yoshida, M	1
Cook, J; Davis, H; Hoos, L; Hwa, JJ; Tetzloff, G; van Heek, M; Zheng, S	1
Black, PN; Orr, DW; Ritchie, SR	1

Reviews

7 review(s) available for ezetimibe and Liver Steatosis

Article	Year
Role of Cholesterol-Associated Steatohepatitis in the Development of NASH. Hepatology communications, 2022, Volume: 6, Issue:1 Topics: Animals; Anticholesteremic Agents; Cholesterol; Cholesterol, Dietary; Ezetimibe; Fatty Liver; Homeostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Non-alcoholic Fatty Liver Disease; Risk Factors	2022
Is the control of dietary cholesterol intake sufficiently effective to ameliorate nonalcoholic fatty liver disease? World journal of gastroenterology, 2010, Feb-21, Volume: 16, Issue:7 Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol, Dietary; Ezetimibe; Fatty Liver; Humans; Liver; Membrane Proteins; Membrane Transport Proteins; Treatment Outcome	2010
Niemann-pick C1-like 1 (NPC1L1) protein in intestinal and hepatic cholesterol transport. Annual review of physiology, 2011, Volume: 73 Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Azetidines; Biliary Tract; Biological Transport; Carrier Proteins; Cholesterol; Endocytosis; Ezetimibe; Fatty Liver; Humans; Intestinal Absorption; Intestinal Mucosa; Intestines; Liver; Membrane Proteins; Membrane Transport Proteins; Mice; Obesity; Phytosterols; Primates	2011
Potential therapeutic uses for ezetimibe beyond lowering LDL-c to decrease cardiovascular events. Diabetes, obesity & metabolism, 2010, Volume: 12, Issue:11 Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Ezetimibe; Fatty Liver; Female; Gallstones; Humans; Intestinal Absorption; Male	2010
Novel role of NPC1L1 in the regulation of hepatic metabolism: potential contribution of ezetimibe in NAFLD/NASH treatment. Current vascular pharmacology, 2011, Volume: 9, Issue:1 Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol; Ezetimibe; Fatty Liver; Humans; Liver; Membrane Proteins; Membrane Transport Proteins; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease	2011
Hepatic Niemann-Pick C1-like 1. Current opinion in lipidology, 2011, Volume: 22, Issue:3 Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol; Ezetimibe; Fatty Liver; Gallstones; Gene Expression; Gene Expression Regulation; Humans; Intestinal Mucosa; Intestines; Liver; Membrane Proteins; Membrane Transport Proteins	2011
Cholesterol-lowering therapy for the treatment of nonalcoholic fatty liver disease: an update. Current opinion in lipidology, 2011, Volume: 22, Issue:6 Topics: Animals; Anticholesteremic Agents; Azetidines; Ezetimibe; Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Non-alcoholic Fatty Liver Disease; Randomized Controlled Trials as Topic	2011

Trials

4 trial(s) available for ezetimibe and Liver Steatosis

Article	Year
[Efficacy and safety of ezetimibe/simvastatin combination therapy in patients with type 2 diabetes and nonalcoholic fatty liver disease]. Orvosi hetilap, 2009, May-24, Volume: 150, Issue:21 Topics: Aged; Alanine Transaminase; Anticholesteremic Agents; Aspartate Aminotransferases; Azetidines; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Fatty Liver; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Simvastatin; Time Factors; Treatment Outcome; Waist Circumference	2009
Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease. Medical science monitor : international medical journal of experimental and clinical research, 2009, Volume: 15, Issue:12 Topics: Aged; Alanine Transaminase; Anticholesteremic Agents; Aspartate Aminotransferases; Azetidines; Cardiovascular Diseases; Cholesterol; Creatine Kinase; Drug Combinations; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Fatty Liver; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Metabolic Syndrome; Middle Aged; Retrospective Studies; Risk Factors; Simvastatin; Triglycerides	2009
Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet. Diabetes care, 2010, Volume: 33, Issue:5 Topics: Adipokines; Aged; alpha-2-HS-Glycoprotein; Anticholesteremic Agents; Apolipoprotein B-100; Azetidines; Biomarkers; Blood Proteins; Body Composition; C-Reactive Protein; Combined Modality Therapy; Diet, Reducing; Ezetimibe; Fatty Liver; Humans; Insulin Resistance; Liver; Middle Aged; Obesity; Patient Compliance; Triglycerides; Weight Loss	2010
Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. Journal of gastroenterology, 2011, Volume: 46, Issue:1 Topics: Adult; Anticholesteremic Agents; Azetidines; Biomarkers; Biopsy; Drug Administration Schedule; Ezetimibe; Fatty Liver; Female; Humans; Liver; Liver Cirrhosis; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Treatment Outcome	2011

Other Studies

31 other study(ies) available for ezetimibe and Liver Steatosis

Article	Year
Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis. Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:3 Topics: Animals; Anticholesteremic Agents; Azetidines; Bile Acids and Salts; Biliary Tract; Biological Transport; Choline Deficiency; Diet; Ezetimibe; Fatty Liver; Glucuronosyltransferase; Intestinal Mucosa; Liver; Male; Membrane Transport Proteins; Methionine; Multidrug Resistance-Associated Proteins; Non-alcoholic Fatty Liver Disease; Rats; Rats, Sprague-Dawley	2012
Pathophysiological importance of bile cholesterol reabsorption: hepatic NPC1L1-exacerbated steatosis and decreasing VLDL-TG secretion in mice fed a high-fat diet. Lipids in health and disease, 2019, Dec-28, Volume: 18, Issue:1 Topics: Animals; Azetidines; Bile; Cholesterol, VLDL; Diet, High-Fat; Ezetimibe; Fatty Liver; Gene Expression Regulation; Humans; Hypercholesterolemia; Intestinal Reabsorption; Liver; Membrane Transport Proteins; Mice; Mice, Transgenic; Triglycerides	2019
Combined use of rosuvastatin and ezetimibe improves hepatic steatosis in patients with dyslipidemia. European journal of gastroenterology & hepatology, 2020, Volume: 32, Issue:12 Topics: Anticholesteremic Agents; Dyslipidemias; Ezetimibe; Fatty Liver; Female; Humans; Male; Retrospective Studies; Rosuvastatin Calcium	2020
Evaluation of the chemopreventive potentials of ezetimibe and aspirin in a novel mouse model of gallbladder preneoplasia. Molecular oncology, 2020, Volume: 14, Issue:11 Topics: Animals; Aspirin; Chemoprevention; Cholecystolithiasis; Cholesterol; Cholesterol, Dietary; Chronic Disease; Diet; Disease Models, Animal; Disease Progression; Ezetimibe; Fatty Liver; Feeding Behavior; Gallbladder Neoplasms; Gallstones; Inflammation; Male; Metaplasia; Mice, Inbred C57BL; Precancerous Conditions; Spleen	2020
Ezetimibe ameliorates steatohepatitis via AMP activated protein kinase-TFEB-mediated activation of autophagy and NLRP3 inflammasome inhibition. Autophagy, 2017, Oct-03, Volume: 13, Issue:10 Topics: AMP-Activated Protein Kinases; Animals; Autophagy; Autophagy-Related Protein 7; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Cells, Cultured; Down-Regulation; Ezetimibe; Fatty Liver; Female; Hep G2 Cells; Humans; Inflammasomes; Inflammation; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; NLR Family, Pyrin Domain-Containing 3 Protein; Signal Transduction	2017
Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome. Journal of hepatology, 2013, Volume: 59, Issue:1 Topics: Adiponectin; Animals; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Diabetes Complications; Drug Therapy, Combination; Ezetimibe; Fatty Liver; Female; Heptanoic Acids; Insulin; Liver; MAP Kinase Signaling System; Metabolic Syndrome; Mice; Mice, Mutant Strains; Mice, Obese; Non-alcoholic Fatty Liver Disease; Pyrroles	2013
Ezetimibe prevents hepatic steatosis induced by a high-fat but not a high-fructose diet. American journal of physiology. Endocrinology and metabolism, 2013, Jul-15, Volume: 305, Issue:2 Topics: Animals; Anticholesteremic Agents; Apolipoproteins B; Azetidines; Azo Compounds; Blotting, Western; Cell Nucleus; Diet; Diet, High-Fat; Electrophoretic Mobility Shift Assay; Enterocytes; Ezetimibe; Fatty Liver; Fructose; Glucose Tolerance Test; Intestinal Mucosa; Intestines; Lipid Metabolism; Lipoproteins; Liver; Male; Mice; Mice, Inbred CBA; Pyruvic Acid; Real-Time Polymerase Chain Reaction; RNA	2013
The Niemann-Pick C1 like 1 (NPC1L1) inhibitor ezetimibe improves metabolic disease via decreased liver X receptor (LXR) activity in liver of obese male mice. Endocrinology, 2014, Volume: 155, Issue:8 Topics: Animals; Anticholesteremic Agents; Azetidines; Cells, Cultured; Diet, High-Fat; Ezetimibe; Fatty Liver; Glucose Metabolism Disorders; Hepatocytes; Intestinal Mucosa; Intestines; Lipid Metabolism; Liver X Receptors; Male; Membrane Transport Proteins; Mice; Mice, Obese; Orphan Nuclear Receptors; Rats; Rats, Sprague-Dawley; Stearoyl-CoA Desaturase	2014
Ezetimibe improves hepatic steatosis in relation to autophagy in obese and diabetic rats. World journal of gastroenterology, 2015, Jul-07, Volume: 21, Issue:25 Topics: Animals; Anticholesteremic Agents; Autophagy; Biomarkers; Blood Glucose; Cells, Cultured; Diabetes Mellitus, Type 2; Disease Models, Animal; Ezetimibe; Fatty Liver; Gene Expression Regulation; Hepatocytes; Lipids; Liver; Macrolides; Male; Obesity; Palmitic Acid; Rats, Inbred OLETF; RNA, Messenger	2015
Evaluation of physicochemical properties and in vivo efficiency of atorvastatin calcium/ezetimibe solid dispersions. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2016, Jan-20, Volume: 82 Topics: Animals; Atorvastatin; Cholesterol; Diet, High-Fat; Drug Combinations; Ezetimibe; Fatty Liver; Hyperlipidemias; Liver; Male; Povidone; Rats, Wistar; Solubility	2016
Long-term administration of a Niemann-Pick C1-like 1 inhibitor, ezetimibe, does not worsen bile lithogenicity in dyslipidemic patients with hepatobiliary diseases. Journal of hepato-biliary-pancreatic sciences, 2016, Volume: 23, Issue:2 Topics: Anticholesteremic Agents; Bile; Cholesterol; Dyslipidemias; Ezetimibe; Fatty Liver; Female; Gallstones; Humans; Lipid Metabolism; Lipoproteins; Male; Middle Aged; Phytosterols; Ursodeoxycholic Acid	2016
Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease. Journal of hepatology, 2009, Volume: 51, Issue:3 Topics: Acarbose; Animals; Anticholesteremic Agents; Azetidines; Carrier Proteins; Cholesterol; Dietary Fats; Disease Models, Animal; Drug Therapy, Combination; Enzyme Inhibitors; Ezetimibe; Fatty Liver; Liver; Liver Cirrhosis; Male; Mice; Mice, Inbred C57BL; PPAR alpha; Receptors, LDL; Sterol Regulatory Element Binding Protein 1; Triglycerides	2009
Inhibition of hepatic Niemann-Pick C1-like 1 improves hepatic insulin resistance. American journal of physiology. Endocrinology and metabolism, 2009, Volume: 297, Issue:5 Topics: Animals; Anticholesteremic Agents; Azetidines; Blotting, Western; Cells, Cultured; Cholesterol; DNA Primers; Endoplasmic Reticulum; Ezetimibe; Fatty Liver; Glucose; Glucose Tolerance Test; Humans; Insulin Resistance; Lipid Metabolism; Liver; Male; Membrane Transport Proteins; Pyruvic Acid; Rats; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; RNA Interference; RNA, Messenger; Superoxides; Triglycerides	2009
NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease. Lipids in health and disease, 2010, Mar-12, Volume: 9 Topics: Adipokines; Adult; Anticholesteremic Agents; Azetidines; Carbohydrates; Cholesterol; Ezetimibe; Fatty Liver; Female; Humans; Liver; Male; Membrane Proteins; Membrane Transport Proteins; Middle Aged; Obesity; Ursodeoxycholic Acid	2010
Ezetimbe as potential treatment for cholesterol gallstones: the need for clinical trials. World journal of gastroenterology, 2010, Apr-07, Volume: 16, Issue:13 Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol; Clinical Trials as Topic; Diet; Drug Evaluation, Preclinical; Ezetimibe; Fatty Liver; Gallstones; Humans; Insulin Resistance; Intestine, Small	2010
Combination of acarbose and ezetimibe prevents non-alcoholic fatty liver disease: a break of intestinal insulin resistance? Journal of hepatology, 2010, Volume: 52, Issue:6 Topics: Acarbose; Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Ezetimibe; Fatty Liver; Humans; Hypoglycemic Agents; Insulin Resistance	2010
A human-type nonalcoholic steatohepatitis model with advanced fibrosis in rabbits. The American journal of pathology, 2010, Volume: 177, Issue:1 Topics: Animals; Anticholesteremic Agents; Antioxidants; Azetidines; Cholesterol, Dietary; Diet; Dietary Fats; Disease Models, Animal; Ezetimibe; Fatty Liver; Fibrosis; Gene Expression Profiling; Glucose; Humans; Liver; Male; Microarray Analysis; Molecular Sequence Data; Oxidative Stress; Rabbits	2010
Ezetimibe as a potential treatment for non-alcoholic fatty liver disease: is the intestine a modulator of hepatic insulin sensitivity and hepatic fat accumulation? Drug discovery today, 2010, Volume: 15, Issue:15-16 Topics: Animals; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Ezetimibe; Fatty Liver; Humans; Inflammation; Insulin Resistance; Liver; Membrane Proteins; Membrane Transport Proteins	2010
Ezetimibe ameliorates cardiovascular complications and hepatic steatosis in obese and type 2 diabetic db/db mice. The Journal of pharmacology and experimental therapeutics, 2010, Volume: 335, Issue:1 Topics: Animals; Anticholesteremic Agents; Azetidines; Blood Pressure; Blood Vessels; Body Composition; Body Weight; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Ezetimibe; Fatty Liver; Glucose Tolerance Test; Immunohistochemistry; In Vitro Techniques; Insulin Resistance; Liver; Male; Mice; Mice, Inbred C57BL; Myocardium; NADPH Oxidases; Obesity; Superoxides; Triglycerides	2010
The fatty acid composition of plasma cholesteryl esters and estimated desaturase activities in patients with nonalcoholic fatty liver disease and the effect of long-term ezetimibe therapy on these levels. Clinica chimica acta; international journal of clinical chemistry, 2010, Nov-11, Volume: 411, Issue:21-22 Topics: Adult; Aged; Azetidines; Case-Control Studies; Cholesterol Esters; Ezetimibe; Fatty Acid Desaturases; Fatty Acids; Fatty Liver; Female; Follow-Up Studies; Humans; Male; Middle Aged; Treatment Outcome	2010
Ezetimibe decreases SREBP-1c expression in liver and reverses hepatic insulin resistance in mice fed a high-fat diet. Metabolism: clinical and experimental, 2011, Volume: 60, Issue:5 Topics: Adiposity; Animals; Anticholesteremic Agents; Azetidines; Bile Acids and Salts; Cells, Cultured; Cholesterol, LDL; Dietary Fats; Ezetimibe; Fatty Liver; Glucose; Insulin Receptor Substrate Proteins; Insulin Resistance; Liver; Male; Mice; Mice, Inbred C57BL; Proto-Oncogene Proteins c-akt; Sterol Regulatory Element Binding Protein 1; Sterol Regulatory Element Binding Protein 2; Triglycerides	2011
Induction of microsomal triglyceride transfer protein expression is a candidate mechanism by which ezetimibe therapy might exert beneficial effects in patients with nonalcoholic steatohepatitis. Journal of gastroenterology, 2011, Volume: 46, Issue:3 Topics: Anticholesteremic Agents; Azetidines; Carrier Proteins; Ezetimibe; Fatty Liver; Humans; Non-alcoholic Fatty Liver Disease	2011
The efficacy of ezetimibe on nonalcoholic fatty liver disease (NAFLD). Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2011, Volume: 108, Issue:8 Topics: Anticholesteremic Agents; Azetidines; Ezetimibe; Fatty Liver; Female; Humans; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Ultrasonography	2011
Ezetimibe reduces fatty acid quantity in liver and decreased inflammatory cell infiltration and improved NASH in medaka model. Biochemical and biophysical research communications, 2012, May-25, Volume: 422, Issue:1 Topics: Animals; Anticholesteremic Agents; Azetidines; Disease Models, Animal; Ezetimibe; Fatty Acids; Fatty Liver; Inflammation; Liver; Non-alcoholic Fatty Liver Disease; Oryzias	2012
Inhibition of intestinal cholesterol absorption by ezetimibe is a novel therapeutic target for fatty liver. Medical hypotheses, 2006, Volume: 66, Issue:4 Topics: Adiponectin; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Ezetimibe; Fatty Liver; Humans; Intestinal Absorption; Intestinal Mucosa; Intestines	2006
Ezetimibe: effective and safe treatment for dyslipidaemia associated with nonalcoholic fatty liver disease. Response to: Toth PP, Davidson MH: simvastatin and ezetimibe: combination therapy for the management of dyslipidaemia. Expert Opin. Pharmacother. ( Expert opinion on drug safety, 2006, Volume: 5, Issue:4 Topics: Anticholesteremic Agents; Azetidines; Drug Combinations; Dyslipidemias; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Fatty Liver; Humans; Insulin Resistance; Simvastatin	2006
Unexpected beneficial effect in the use of ezetimibe in non-alcoholic fatty liver disease. Medical hypotheses, 2006, Volume: 67, Issue:6 Topics: Alanine Transaminase; Anticholesteremic Agents; Azetidines; Cholesterol; Ezetimibe; Fatty Liver; Humans; Liver Function Tests; Time Factors; Treatment Outcome; Ultrasonography	2006
Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease. World journal of gastroenterology, 2006, Jul-21, Volume: 12, Issue:27 Topics: Animals; Anticholesteremic Agents; Azetidines; Choline Deficiency; Drug Therapy, Combination; Ezetimibe; Fats; Fatty Liver; Hypoglycemic Agents; Lipid Peroxidation; Liver; Male; Metformin; Oxidative Stress; Rats; Rats, Sprague-Dawley; Rosiglitazone; Tetrazoles; Thiazolidinediones; Tumor Necrosis Factor-alpha; Valine; Valsartan	2006
Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS letters, 2007, Dec-11, Volume: 581, Issue:29 Topics: Animals; Anticholesteremic Agents; Azetidines; Blood Glucose; Body Weight; Cells, Cultured; Disease Models, Animal; Dyslipidemias; Ezetimibe; Fatty Liver; Hepatocytes; Insulin Resistance; Lipids; Metabolic Syndrome; Obesity; Rats; Rats, Zucker; Time Factors	2007
Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice. European journal of pharmacology, 2008, Apr-14, Volume: 584, Issue:1 Topics: Alanine Transaminase; Animals; Anticholesteremic Agents; Azetidines; Cholesterol Esters; Cholesterol, Dietary; Dietary Fats; Disease Models, Animal; Dose-Response Relationship, Drug; Ezetimibe; Fatty Liver; Hepatomegaly; Liver; Liver Cirrhosis; Mice; Mice, Inbred C57BL; Obesity; Time Factors; Triglycerides	2008
Severe jaundice following treatment with ezetimibe. European journal of gastroenterology & hepatology, 2008, Volume: 20, Issue:6 Topics: Anticholesteremic Agents; Azetidines; Ezetimibe; Fatty Liver; Female; Humans; Hyperbilirubinemia; Jaundice; Middle Aged	2008